collection
https://read.qxmd.com/read/27596132/icosapent-ethyl-eicosapentaenoic-acid-ethyl-ester-effects-on-remnant-like-particle-cholesterol-from-the-marine-and-anchor-studies
#1
RANDOMIZED CONTROLLED TRIAL
Christie M Ballantyne, Harold E Bays, Sephy Philip, Ralph T Doyle, Rene A Braeckman, William G Stirtan, Paresh N Soni, Rebecca A Juliano
BACKGROUND AND AIMS: Remnant-like particle cholesterol (RLP-C) is atherogenic and may increase atherosclerotic cardiovascular disease risk. Icosapent ethyl is a high-purity prescription eicosapentaenoic acid ethyl ester (approved as an adjunct to diet to reduce triglyceride [TG] levels in adult patients with TGs ≥500 mg/dL [≥5.65 mmol/L] at 4 g/day). In the MARINE and ANCHOR studies, icosapent ethyl reduced TG and other atherogenic lipid parameter levels without increasing low-density lipoprotein cholesterol (LDL-C) levels...
October 2016: Atherosclerosis
https://read.qxmd.com/read/30415628/cardiovascular-risk-reduction-with-icosapent-ethyl-for-hypertriglyceridemia
#2
RANDOMIZED CONTROLLED TRIAL
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, Christie M Ballantyne
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1...
January 3, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30898607/effects-of-icosapent-ethyl-on-total-ischemic-events-from-reduce-it
#3
RANDOMIZED CONTROLLED TRIAL
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, John Gregson, Stuart J Pocock, Christie M Ballantyne
BACKGROUND: In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with elevated triglycerides receiving statins. These patients are at risk for not only first but also subsequent ischemic events. OBJECTIVES: Pre-specified analyses determined the extent to which icosapent ethyl reduced total ischemic events. METHODS: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) randomized 8,179 statin-treated patients with triglycerides ≥135 and <500 mg/dl (median baseline of 216 mg/dl) and low-density lipoprotein cholesterol >40 and ≤100 mg/dl (median baseline of 75 mg/dl), and a history of atherosclerosis (71% patients) or diabetes (29% patients) to icosapent ethyl 4 g/day or placebo...
June 11, 2019: Journal of the American College of Cardiology
https://read.qxmd.com/read/28606345/empa-reg-outcome-the-cardiologist-s-point-of-view
#4
REVIEW
Son V Pham, Robert J Chilton
Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling...
July 1, 2017: American Journal of Cardiology
https://read.qxmd.com/read/31251325/a-practical-approach-to-low-dose-aspirin-for-primary-prevention
#5
Kim F Chiang, Shreya J Shah, Randall S Stafford
No abstract text is available yet for this article.
June 28, 2019: JAMA
https://read.qxmd.com/read/29676281/risk-thresholds-for-alcohol-consumption-combined-analysis-of-individual-participant-data-for-599-912-current-drinkers-in-83-prospective-studies
#6
Angela M Wood, Stephen Kaptoge, Adam S Butterworth, Peter Willeit, Samantha Warnakula, Thomas Bolton, Ellie Paige, Dirk S Paul, Michael Sweeting, Stephen Burgess, Steven Bell, William Astle, David Stevens, Albert Koulman, Randi M Selmer, W M Monique Verschuren, Shinichi Sato, Inger Njølstad, Mark Woodward, Veikko Salomaa, Børge G Nordestgaard, Bu B Yeap, Astrid Fletcher, Olle Melander, Lewis H Kuller, Beverley Balkau, Michael Marmot, Wolfgang Koenig, Edoardo Casiglia, Cyrus Cooper, Volker Arndt, Oscar H Franco, Patrik Wennberg, John Gallacher, Agustín Gómez de la Cámara, Henry Völzke, Christina C Dahm, Caroline E Dale, Manuela M Bergmann, Carlos J Crespo, Yvonne T van der Schouw, Rudolf Kaaks, Leon A Simons, Pagona Lagiou, Josje D Schoufour, Jolanda M A Boer, Timothy J Key, Beatriz Rodriguez, Conchi Moreno-Iribas, Karina W Davidson, James O Taylor, Carlotta Sacerdote, Robert B Wallace, J Ramon Quiros, Rosario Tumino, Dan G Blazer, Allan Linneberg, Makoto Daimon, Salvatore Panico, Barbara Howard, Guri Skeie, Timo Strandberg, Elisabete Weiderpass, Paul J Nietert, Bruce M Psaty, Daan Kromhout, Elena Salamanca-Fernandez, Stefan Kiechl, Harlan M Krumholz, Sara Grioni, Domenico Palli, José M Huerta, Jackie Price, Johan Sundström, Larraitz Arriola, Hisatomi Arima, Ruth C Travis, Demosthenes B Panagiotakos, Anna Karakatsani, Antonia Trichopoulou, Tilman Kühn, Diederick E Grobbee, Elizabeth Barrett-Connor, Natasja van Schoor, Heiner Boeing, Kim Overvad, Jussi Kauhanen, Nick Wareham, Claudia Langenberg, Nita Forouhi, Maria Wennberg, Jean-Pierre Després, Mary Cushman, Jackie A Cooper, Carlos J Rodriguez, Masaru Sakurai, Jonathan E Shaw, Matthew Knuiman, Trudy Voortman, Christa Meisinger, Anne Tjønneland, Hermann Brenner, Luigi Palmieri, Jean Dallongeville, Eric J Brunner, Gerd Assmann, Maurizio Trevisan, Richard F Gillum, Ian Ford, Naveed Sattar, Mariana Lazo, Simon G Thompson, Pietro Ferrari, David A Leon, George Davey Smith, Richard Peto, Rod Jackson, Emily Banks, Emanuele Di Angelantonio, John Danesh
BACKGROUND: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. METHODS: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank)...
April 14, 2018: Lancet
https://read.qxmd.com/read/30480768/first-line-drugs-inhibiting-the-renin-angiotensin-system-versus-other-first-line-antihypertensive-drug-classes-for-hypertension
#7
Yu Jie Chen, Liang Jin Li, Wen Lu Tang, Jia Yang Song, Ru Qiu, Qian Li, Hao Xue, James M Wright
BACKGROUND: This is the first update of a Cochrane Review first published in 2015. Renin angiotensin system (RAS) inhibitors include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and renin inhibitors. They are widely prescribed for treatment of hypertension, especially for people with diabetes because of postulated advantages for reducing diabetic nephropathy and cardiovascular morbidity and mortality. Despite widespread use for hypertension, the efficacy and safety of RAS inhibitors compared to other antihypertensive drug classes remains unclear...
November 14, 2018: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/28459663/does-evolocumab-as-a-pcsk9-inhibitor-ameliorate-the-lipid-profile-in-familial-hypercholesterolemia-patients-a-meta-analysis-of-randomized-controlled-trials
#8
REVIEW
Seyyed Majid Eslami, Shekoufeh Nikfar, Maryam Ghasemi, Mohammad Abdollahi
Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a member of regulatory serine proteases which is mostly expressed in liver. In the physiological condition, LDL-C binds to LDL receptors (LDLRs) and via endocytosis, LDLRs are degraded. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of extracellular LDLRs, and then physiological recycling of LDLRs from surface of liver is cancelled, resulting in elevation of circulating LDL-C in plasma. To evaluate whether evolucomab, as PCSK9 inhibitor monoclonal antibody, ameliorates lipid profile in familial hypercholesterolemia (FH) patients, this meta-analysis has been conducted...
2017: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/29809241/clonal-hematopoiesis-confers-predisposition-to-both-cardiovascular-disease-and-cancer-a-newly-recognized-link-between-two-major-killers
#9
Benjamin L Ebert, Peter Libby
No abstract text is available yet for this article.
July 17, 2018: Annals of Internal Medicine
https://read.qxmd.com/read/26791059/utility-of-nontraditional-risk-markers-in-atherosclerotic-cardiovascular-disease-risk-assessment
#10
Joseph Yeboah, Rebekah Young, Robyn L McClelland, Joseph C Delaney, Tamar S Polonsky, Farah Z Dawood, Michael J Blaha, Michael D Miedema, Christopher T Sibley, J Jeffrey Carr, Gregory L Burke, David C Goff, Bruce M Psaty, Philip Greenland, David M Herrington
BACKGROUND: The improvement in discrimination gained by adding nontraditional cardiovascular risk markers cited in the 2013 American College of Cardiology/American Heart Association cholesterol guidelines to the atherosclerotic cardiovascular disease (ASCVD) risk estimator (pooled cohort equation [PCE]) is untested. OBJECTIVES: This study assessed the predictive accuracy and improvement in reclassification gained by the addition of the coronary artery calcium (CAC) score, the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) levels, and family history (FH) of ASCVD to the PCE in participants of MESA (Multi-Ethnic Study of Atherosclerosis)...
January 19, 2016: Journal of the American College of Cardiology
https://read.qxmd.com/read/23073674/recommendations-on-screening-for-type-2-diabetes-in-adults
#11
Kevin Pottie, Alejandra Jaramillo, Gabriela Lewin, Jim Dickinson, Neil Bell, Paula Brauer, Lesley Dunfield, Michel Joffres, Harminder Singh, Marcello Tonelli
No abstract text is available yet for this article.
October 16, 2012: Canadian Medical Association Journal: CMAJ
https://read.qxmd.com/read/27923853/-ten-commandments-from-the-2016-esc-eas-guidelines-for-the-management-of-dyslipidaemias
#12
(no author information available yet)
No abstract text is available yet for this article.
October 14, 2016: European Heart Journal
https://read.qxmd.com/read/27551034/association-between-resting-heart-rate-and-coronary-artery-disease-stroke-sudden-death-and-noncardiovascular-diseases-a-meta-analysis
#13
Dongfeng Zhang, Weijing Wang, Fang Li
BACKGROUND: Resting heart rate is linked to risk of coronary artery disease, stroke, sudden death and noncardiovascular diseases. We conducted a meta-analysis to assess these associations in general populations and in populations of patients with hypertension or diabetes mellitus. METHODS: We searched PubMed, Embase and MEDLINE from inception to Mar. 5, 2016. We used a random-effects model to combine study-specific relative risks (RRs). We used restricted cubic splines to assess the dose-response relation...
October 18, 2016: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://read.qxmd.com/read/26606383/exercise-as-medicine-evidence-for-prescribing-exercise-as-therapy-in-26-different-chronic-diseases
#14
REVIEW
B K Pedersen, B Saltin
This review provides the reader with the up-to-date evidence-based basis for prescribing exercise as medicine in the treatment of 26 different diseases: psychiatric diseases (depression, anxiety, stress, schizophrenia); neurological diseases (dementia, Parkinson's disease, multiple sclerosis); metabolic diseases (obesity, hyperlipidemia, metabolic syndrome, polycystic ovarian syndrome, type 2 diabetes, type 1 diabetes); cardiovascular diseases (hypertension, coronary heart disease, heart failure, cerebral apoplexy, and claudication intermittent); pulmonary diseases (chronic obstructive pulmonary disease, asthma, cystic fibrosis); musculo-skeletal disorders (osteoarthritis, osteoporosis, back pain, rheumatoid arthritis); and cancer...
December 2015: Scandinavian Journal of Medicine & Science in Sports
https://read.qxmd.com/read/26245731/low-alt-levels-independently-associated-with-22-year-all-cause-mortality-among-coronary-heart-disease-patients
#15
N Peltz-Sinvani, R Klempfner, E Ramaty, B A Sela, I Goldenberg, G Segal
BACKGROUND: Low alanine aminotransferase (ALT) blood levels are known to be associated with frailty and increased risk of long-term mortality in certain populations. However, the contribution of this marker to long-term outcome has not been assessed in patients with chronic coronary heart disease. OBJECTIVE: The aim of the current study was to assess the association between low ALT values and long-term, 22.8-year, all-cause mortality in this population. PARTICIPANTS: We examined the association of low ALT (<17 IU/l) with long-term all-cause mortality in the Bezafibrate Infarction Prevention (BIP) Registry population...
February 2016: Journal of General Internal Medicine
https://read.qxmd.com/read/27016105/long-term-effectiveness-and-safety-of-pravastatin-in-patients-with-coronary-heart-disease-sixteen-years-of-follow-up-of-the-lipid-study
#16
REVIEW
Wendy E Hague, John Simes, Adrienne Kirby, Anthony C Keech, Harvey D White, David Hunt, Paul J Nestel, David M Colquhoun, Helen Pater, Ralph A Stewart, David R Sullivan, Peter L Thompson, Malcolm West, Paul P Glasziou, Andrew M Tonkin
BACKGROUND: We aimed to assess the long-term effects of treatment with statin therapy on all-cause mortality, cause-specific mortality, and cancer incidence from extended follow-up of the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial. METHODS AND RESULTS: LIPID initially compared pravastatin and placebo over 6 years in 9014 patients with previous coronary heart disease. After the double-blind period, all patients were offered open-label statin therapy...
May 10, 2016: Circulation
https://read.qxmd.com/read/26881813/discriminative-power-of-the-heart-score-for-obstructive-coronary-artery-disease-in-acute-chest-pain-patients-referred-for-ccta
#17
Adriana Q Kolff, Michiel J Bom, Remco J J Knol, Friso M van de Zant, Petrus M van der Zee, Jan H Cornel
OBJECTIVE: To investigate the ability of the HEART score to predict the presence of obstructive coronary artery disease (CAD) determined by coronary computed tomography angiography (CCTA) and its ability to predict the occurrence of major adverse cardiac events (MACE) in patients referred for CCTA after emergency department (ED) presentation. METHODS: From December 2011 to August 2014, 710 ED patients with chest pain who underwent CCTA within 30 days were included...
March 2016: Critical Pathways in Cardiology
https://read.qxmd.com/read/26906397/the-addition-of-depression-to-the-framingham-risk-equation-model-for-predicting-coronary-heart-disease-risk-in-women
#18
Adrienne O'Neil, Aaron J Fisher, Katherine J Kibbey, Felice N Jacka, Mark A Kotowicz, Lana J Williams, Amanda L Stuart, Michael Berk, Paul A Lewandowski, John J Atherton, Craig B Taylor, Julie A Pasco
BACKGROUND: Depression is widely considered to be an independent and robust predictor of Coronary Heart Disease (CHD), however is seldom considered in the context of formal risk assessment. We assessed whether the addition of depression to the Framingham Risk Equation (FRE) improved accuracy for predicting 10-year CHD in a sample of women. DESIGN: A prospective, longitudinal design comprising an age-stratified, population-based sample of Australian women collected between 1993 and 2011 (n=862)...
June 2016: Preventive Medicine
https://read.qxmd.com/read/27012910/how-does-sprint-systolic-blood-pressure-intervention-trial-direct-hypertension-treatment-targets-for-ckd
#19
EDITORIAL
Sandra J Taler
No abstract text is available yet for this article.
July 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://read.qxmd.com/read/25838421/high-density-lipoprotein-hdl-phospholipid-content-and-cholesterol-efflux-capacity-are-reduced-in-patients-with-very-high-hdl-cholesterol-and-coronary-disease
#20
Anandita P Agarwala, Amrith Rodrigues, Marjorie Risman, Mary McCoy, Kevin Trindade, Liming Qu, Marina Cuchel, Jeffrey Billheimer, Daniel J Rader
OBJECTIVE: Plasma levels of high-density lipoprotein cholesterol (HDL-C) are strongly inversely associated with coronary artery disease (CAD), and high HDL-C is generally associated with reduced risk of CAD. Extremely high HDL-C with CAD is an unusual phenotype, and we hypothesized that the HDL in such individuals may have an altered composition and reduced function when compared with controls with similarly high HDL-C and no CAD. APPROACH AND RESULTS: Fifty-five subjects with very high HDL-C (mean, 86 mg/dL) and onset of CAD at the age of ≈ 60 years with no known risk factors for CAD (cases) were identified through systematic recruitment...
June 2015: Arteriosclerosis, Thrombosis, and Vascular Biology
label_collection
label_collection
2764
1
2
2016-03-31 13:32:36
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"